India’s Bharat Enters Zika Fray With Two Vaccine Candidates
This article was originally published in PharmAsia News
Executive Summary
India's Bharat Biotech says it is working on two vaccines to tackle the rapidly spreading Zika virus, one of which is ready for preclinical trials.
You may also be interested in...
Bharat Enters Chikungunya Fray As Vaccine Moves Into Trials
Indian vaccine developer Bharat Biotech has moved a candidate vaccine for chikungunya into Phase I trials, joining over a dozen firms worldwide hoping to commercialize the first vaccine to halt transmission of the painful mosquito-borne illness, which is spreading globally.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.